CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 604,214	$ 809,102
Marketable securities	244,965	236,121
Accounts receivable - trade, net	1,450,572	1,152,489
Accounts Receivable from Sanofi	173,782	153,152
Accounts receivable from Bayer	240,867	162,152
Inventories	303,294	238,578
Prepaid expenses and other current assets	115,685	163,501
Total current assets	3,133,379	2,915,095
Marketable securities	555,210	632,162
Property, plant, and equipment, net	1,666,391	1,594,120
Deferred tax assets	543,689	461,945
Other assets	5,791	5,810
Total assets	5,904,460	5,609,132
Current liabilities:
Accounts payable and accrued expenses	733,276	644,112
Deferred revenue from Sanofi, current portion	99,314	101,573
Deferred revenue - other, current portion	73,626	51,914
Other current liabilities	13,508	13,563
Total current liabilities	919,724	811,162
Deferred revenue from Sanofi	565,773	582,664
Deferred Revenue - other	170,658	82,015
Facility lease obligations	362,230	362,919
Other long-term liabilities	120,993	115,535
Total liabilities	2,139,378	1,954,295
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,049,651	3,099,526
Retained earnings	1,018,436	852,700
Accumulated other comprehensive income	4,364	8,572
Treasury stock	(307,478)	(306,069)
Total stockholders' equity	3,765,082	3,654,837
Total liabilities and stockholders' equity	5,904,460	5,609,132
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 107	$ 106